Results 31 to 40 of about 6,652 (162)
PM&R, EarlyView.Abstract Background The effectiveness of platelet‐rich plasma (PRP) injections in chronic tendinopathies remains debated. Although the product's characteristics play a role, the impact of postinjection recommendations remains poorly investigated. Objective To establish principles and guidelines for post‐PRP injection rehabilitation and return to ...
Vincent Gremeaux +12 more
wiley +1 more source
The Journal of Physiology, EarlyView.Abstract figure legend A mechanistic framework linking sex‐dependent dynamical instability to proarrhythmic risk. Sex‐specific human ventricular models show that upstream modulators, including biological sex, hormones, drugs and heart disease, promote steeper APD restitution in female than male and enhance dynamical instability.
Daisuke Sato +3 more
wiley +1 more source
DEN Open, Volume 7, Issue 1, April 2027.ABSTRACT Objectives Post‐endoscopic retrograde cholangiopancreatography (post‐ERCP) bleeding occurs more frequently in dialysis patients than in non‐dialysis patients. This study aimed to identify risk factors for post‐ERCP bleeding following stone removal in patients undergoing dialysis.
Masaki Nishimura +16 more
wiley +1 more source
Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate
Drug Design, Development and Therapy, 2015 Jae Hong Seo, Jung Bae Park, Woong-Kee Choi, Sunhwa Park, Yun Jin Sung, Euichaul Oh, Soo Kyung Bae College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, South Korea Objective ...
Seo JH +6 more
doaj
Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis. [PDF]
PLoS ONE, 2015 Cilostazol has been reported to alleviate the metabolic syndrome induced by increased intracellular adenosine 3',5'-cyclic monophosphate (cAMP) levels, which is also associated with osteoclast (OC) differentiation. We hypothesized that bone loss might be
Ke Ke +6 more
doaj +1 more source
Cilostazol for secondary stroke prevention: systematic review and meta-analysis
Stroke and Vascular Neurology, 2021 Background Stroke is one of the leading causes of death worldwide. Cilostazol, an antiplatelet and phosphodiesterase 3 inhibitor, has not been clearly established for ischaemic stroke use.
Leonard LL Yeo +7 more
doaj +1 more source
Risk of Delayed Post‐polypectomy Bleeding in Patients With Antithrombotic Therapy
DEN Open, Volume 7, Issue 1, April 2027.Antithrombotic therapy is associated with an increased risk of delayed post‐polypectomy bleeding after endoscopic resection of colorectal polyps ≤15 mm. Despite this increased risk, overall bleeding rates remain low in both per‐patient and per‐lesion analyses. ABSTRACT Objectives Recent changes in the perioperative management of antithrombotic therapy (
Rumiko Tsuboi +18 more
wiley +1 more source
Preparation and in-vitro evaluation of cilostazol self-emulsifying drug delivery system
Al-Mustansiriyah Journal of Pharmaceutical Sciences, 2020 This work reported a first liquid self-nanoemulsifying drug delivery system (SEDD) of cilostazol using oleic acid as oil phase, tween 80 as surfactant, and transcutol as co-surfactant.
Ali N. Wannas, Nidhal K. Maraie
doaj +1 more source
BJUI Compass, Volume 7, Issue 8, August 2026.Abstract Objectives This study aims to evaluate the safety of transperineal prostate biopsy performed with continued antiplatelet and anticoagulant therapies under caudal anaesthesia. Patients and Methods A total of 620 consecutive patients who underwent transperineal ultrasound‐guided prostate biopsy at a tertiary care centre in Japan from March 2023 ...
Naoki Akagi +13 more
wiley +1 more source
Russian Open Medical Journal, 2013 Cilostazol is a phosphodiesterase III inhibitor, which was approved by FDA (food and drug administration) for intermittent claudication in 1999. What made it known to cardiologists is the Cilostazol for Restenosis Trial (CREST), in which cilostazol was ...
Lihua Zhong +3 more
doaj